Peptide Cancer Vaccine Market: By Type, By Application, and Region Forecast 2019-2030

download arrow download arrow Download Free Sample
settings arrow settings arrow email us

Peptide Cancer Vaccine Market Size, Share, Growth, Trends, and Global Industry Analysis: By Type (Multivalent Peptide Vaccine, Peptide Cocktail Type, Personalized Peptide Vaccine, Peptide-Pulsed Dendritic Cancer Vaccine, Hybrid Peptide Vaccine, Others), By Application (Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer, and Others), and Region Forecast 2019-2030

checked icon arrow_drop_down
checked icon Single User License $4400 $3520
checked icon Multiple User License $6600 $5280
checked icon Corporate User License $8900 $7120

Peptide Cancer Vaccine Market size was valued at US$ 654.6 million in 2023, It is expected to reach a value of US$ 1,701.5 million by 2030, growing at a CAGR of 16.5%  from 2024 to 2030. The global market provides a detailed overview, which has been segmented by type, and application. The market has been segmented into Multivalent Peptide Vaccines, Peptide Cocktail Types, Personalized Peptide Vaccines, Peptide-Pulsed Dendritic Cancer Vaccines, Hybrid Peptide Vaccine, and Others. The peptide cocktail type segment is likely the most significant and fastest-growing in terms of type. Based on the application, the peptide cancer vaccine is segmented into Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer, and Others. According to Precision Business Insights, the breast cancer segment is predicted to register the fastest growth rate during the forecast period.

Peptide Cancer Vaccine Market Key Development

  • In December 2021, ISA pharmaceuticals presented key learnings in cancer vaccine development in an educational session at the ESMO Immune-Oncology Congress 2021.

summary download arrow Download Free Sample

Peptide Cancer Vaccine Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

16.5%

Largest Market

North America

Fastest Growing Market

Asia-Pacific

Peptide Cancer Vaccine Market Dynamics

The ability to quickly synthesize, prepare and use peptide vaccines, their use in clinical settings, and adaptability to changing antigens. Reduced risk of anaphylaxis caused by antigens are benefits that are anticipated to drive market growth for peptide cancer vaccines shortly.

Peptide Cancer Vaccine Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2024-2030

Market Size in 2023

US$ 654.6 million

Market Size in 2030

US$ 1,701.5 million

Market CAGR

16.5%

By Type

  • Multivalent Peptide Vaccine,
  • Peptide Cocktail Type,
  • Personalized Peptide Vaccine,
  • Peptide-Pulsed Dendritic Cancer Vaccine,
  • Hybrid Peptide Vaccine,
  • Others

By Application

  • Breast Cancer,
  • Lung Cancer,
  • Melanoma,
  • Prostate Cancer and
  • Others

By Region

  • North America (U.S., Canada)
  • Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
  • Asia-Pacific (China, India, Japan, Australia, Southeast Asia, Rest of Asia Pacific)
  • Latin America (Mexico, Brazil, Argentina, Columbia, Rest of Latin America)
  • Middle East & Africa (GCC, Egypt, Nigeria, South Africa, Rest of Middle East and Africa)

Key Features of the Report

  • The peptide cancer vaccine market report provides granular level information about the Market size, regional Market share, historic Market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key Market developments, and key strategies.
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the Market.
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the Market.
  • The report provides a plethora of information about Market entry strategies, regulatory framework, and reimbursement scenarios.
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter's Five Force Analysis.

Download Free Sample Report

I accept the Terms and Conditions,Disclaimers, GDPR Policy

Frequently Asked Questions

The peptide cancer vaccine market size was valued at US$ 654.6 Mn in 2023 and is set to reach US$ 1,701.5 Mn by 2030 at a CAGR of 16.5% from 2024-2030

The market key players are: Antigen Express BioLife Science Boston Biomedical Enzo Life Science Galena Biopharma Generex Biotechnology Generex Biotechnology Corporation Immatics Biotechnologies Immunomedics ISA Pharmaceuticals OncoTherapy Science Sellas TapImmune

The market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1. Executive Summary
2. Global Peptide Cancer Vaccine Market Introduction
2.1. Global Peptide Cancer Vaccine Market Taxonomy
2.2. Global Peptide Cancer Vaccine Market Definitions
2.2.1. By Type
2.2.2. By Application
2.2.3. By Region
3. Global Peptide Cancer Vaccine Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Peptide Cancer Vaccine Market Dynamic Factors - Impact Analysis
3.6. Global Peptide Cancer Vaccine Market Competition Landscape
4. Global Peptide Cancer Vaccine Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Peptide Cancer Vaccine Market, By Type, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) 
5.1. Multivalent Peptide Vaccine
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Peptide Cocktail Types
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Personalized Peptide Vaccine
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Peptide-Pulsed Dendritic Cancer Vaccine
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Hybrid Peptide Vaccine
5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Others
5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
6. Global Peptide Cancer Vaccine Market, By Application, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) 
6.1. Breast Cancer
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Lung Cancer
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Melanoma
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Prostate Cancer
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Others
6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
7. Global Peptide Cancer Vaccine Market Forecast, By Region, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) 
7.1. North America
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Asia-Pacific
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Global Peptide Cancer Vaccine Market - Opportunity Analysis Index, By Type, Application, and Region, 2024 - 2030
8. North America Peptide Cancer Vaccine Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) 
8.1. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.1.1. Multivalent Peptide Vaccine
8.1.2. Peptide Cocktail Type
8.1.3. Personalized Peptide Vaccine
8.1.4. Peptide-Pulsed Dendritic Cancer Vaccine
8.1.5. Hybrid Peptide Vaccine
8.1.6. Others
8.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.2.1. Breast Cancer
8.2.2. Lung Cancer
8.2.3. Melanoma
8.2.4. Prostate Cancer
8.2.5. Others
8.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
8.3.1. USA
8.3.2. Canada
8.4. North America Peptide Cancer Vaccine Market - Opportunity Analysis Index, By Type, Application, and Country, 2024 - 2030
8.5. North America Peptide Cancer Vaccine Market Dynamics Trends
9. Europe Peptide Cancer Vaccine Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) 
9.1. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Multivalent Peptide Vaccine
9.1.2. Peptide Cocktail Type
9.1.3. Personalized Peptide Vaccine
9.1.4. Peptide-Pulsed Dendritic Cancer Vaccine
9.1.5. Hybrid Peptide Vaccine
9.1.6. Others
9.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.2.1. Breast Cancer
9.2.2. Lung Cancer
9.2.3. Melanoma
9.2.4. Prostate Cancer
9.2.5. Others
9.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.3.1. Germany
9.3.2. UK
9.3.3. France
9.3.4. Spain
9.3.5. Italy
9.3.6. Russia
9.3.7. Rest of Europe
9.4. Europe Peptide Cancer Vaccine Market - Opportunity Analysis Index, By Type, Application, and Country, 2024 - 2030
9.5. Europe Peptide Cancer Vaccine Market Dynamics Trends
10. Asia-Pacific Peptide Cancer Vaccine Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
10.1. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Multivalent Peptide Vaccine
10.1.2. Peptide Cocktail Type
10.1.3. Personalized Peptide Vaccine
10.1.4. Peptide-Pulsed Dendritic Cancer Vaccine
10.1.5. Hybrid Peptide Vaccine
10.1.6. Others
10.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Breast Cancer
10.2.2. Lung Cancer
10.2.3. Melanoma
10.2.4. Prostate Cancer
10.2.5. Others
10.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.3.1. China
10.3.2. India
10.3.3. Japan
10.3.4. ASEAN
10.3.5. Australia & New Zealand
10.3.6. Rest of Asia-Pacific
10.4. Asia-Pacific Peptide Cancer Vaccine Market - Opportunity Analysis Index, By Type, Application, and Country, 2024 - 2030
10.5. Asia-Pacific Peptide Cancer Vaccine Market Dynamics Trends
11. Latin America Peptide Cancer Vaccine Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) 
11.1. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Multivalent Peptide Vaccine
11.1.2. Peptide Cocktail Type
11.1.3. Personalized Peptide Vaccine
11.1.4. Peptide-Pulsed Dendritic Cancer Vaccine
11.1.5. Hybrid Peptide Vaccine
11.1.6. Others
11.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Breast Cancer
11.2.2. Lung Cancer
11.2.3. Melanoma
11.2.4. Prostate Cancer
11.2.5. Others
11.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.3.1. Brazil
11.3.2. Mexico
11.3.3. Argentina
11.3.4. Rest of Latin America
11.4. Latin America Peptide Cancer Vaccine Market - Opportunity Analysis Index, By Type, Application, and Country, 2024 - 2030
11.5. Latin America Peptide Cancer Vaccine Market Dynamics Trends
12. Middle East and Africa Peptide Cancer Vaccine Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) 
12.1. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Multivalent Peptide Vaccine
12.1.2. Peptide Cocktail Type
12.1.3. Personalized Peptide Vaccine
12.1.4. Peptide-Pulsed Dendritic Cancer Vaccine
12.1.5. Hybrid Peptide Vaccine
12.1.6. Others
12.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Breast Cancer
12.2.2. Lung Cancer
12.2.3. Melanoma
12.2.4. Prostate Cancer
12.2.5. Others
12.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.3.1. Gulf Cooperation Council (GCC) Countries
12.3.2. Israel
12.3.3. South Africa
12.3.4. Rest of MEA
12.4. MEA Peptide Cancer Vaccine Market - Opportunity Analysis Index, By Type, Application, and Country, 2024 - 2030
12.5. MEA Peptide Cancer Vaccine Market Dynamics Trends
13. Competition Landscape 
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Type Offerings, Key Developments, Strategies, and SWOT Analysis)
13.2.1. Antigen Express
13.2.2. BioLife Science
13.2.3. Boston Biomedical
13.2.4. Enzo Life Science
13.2.5. Galena Biopharma
13.2.6. Generex Biotechnology
13.2.7. Generex Biotechnology Corporation
13.2.8. Immatics Biotechnologies
13.2.9. Immunomedics
13.2.10. ISA Pharmaceuticals
13.2.11. OncoTherapy Science
13.2.12. Sellas
13.2.13. TapImmune
13.2.14. VAXON Biotech
14. Research Methodology
15. Key Assumptions and Acronyms

Key Market Players

  • Antigen Express
  • BioLife Science
  • Boston Biomedical
  • Enzo Life Science
  • Galena Biopharma
  • Generex Biotechnology
  • Generex Biotechnology Corporation
  • Immatics Biotechnologies
  • Immunomedics
  • ISA Pharmaceuticals
  • OncoTherapy Science
  • Sellas
  • TapImmune

Related Industry Reports

Chronic Refractory Gout Pharmaceuticals Market

Familial Mediterranean Fever Pharmaceuticals Market

Australia Point of Care Diagnostics Market

Aseptic Sampling Market